Individuals with generalized anxiety disorder (GAD), a condition characterized by daily excessive worry lasting at least six months, have a high relapse rate even after receiving treatment. Artificial ...

Please provide your email address to receive an email when new articles are posted on . Treatment of generalized anxiety disorder with an antidepressant increased the treatment response rate by 41%.

In the mental health field, we tend to pathologize and diagnose even commonly encountered challenges. Through the lens of human experience, however, we can recognize that some emotional and mental ...

Generalized anxiety disorder affects 1 in 20 U.S. adults. Those with serious symptoms may isolate themselves to the point they rarely leave their home and are unable to work and build meaningful ...

NEW YORK (Reuters Health) - The results of a study published in the April issue of the Journal of Clinical Psychiatry indicate that treatment with duloxetine, sold under the trade name Cymbalta, ...

In a world of constant connectivity and mounting pressures, generalized anxiety disorder (GAD) has emerged as a significant mental health challenge affecting millions. Recent studies show that anxiety ...

Inc. has recently rebranded as Deinium Therapeutics Inc., is changing its Nasdaq ticker to DFTX, and outlined a late-stage ...

- Panorama is the second Phase 3 trial of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for ...

NEW YORK--(BUSINESS WIRE)--Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product ...

(RTTNews) - Viatris Inc. (VTRS), a healthcare company, Monday said it has submitted Supplemental New Drug Application to Japan's Ministry of Health, Labor and Welfare (MHLW) for Effexor to treat ...